The European Commission has approved RINVOQ (upadacitinib) for treating active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older who have not responded well or are intolerant to other treatments. This approval is based on positive results from the Phase 1 SELECT-YOUTH study and adult rheumatoid arthritis data, showing significant improvements in disease activity, pain, and physical function with a favorable safety profile. RINVOQ offers a new oral treatment option for this debilitating condition, potentially improving remission rates and quality of life for pediatric patients. AbbVie continues to expand RINVOQ's use across multiple immune-mediated diseases in the EU.
AbbVie Inc holds a substantial market cap of $466.45 billion and offers a dividend yield of 2.62%, reflecting its strong position in the health sector. As of September 22, 2026, 13:11 WIB, AbbVie's stock price on Pluang is USD 263.98 with a slight 1-day decline of 0.21%. The recent European Commission approval of RINVOQ for pediatric arthritis adds to AbbVie's expanding portfolio in immune-mediated diseases, potentially influencing investor interest despite the current modest selling pressure on the platform.
AbbVie and Iambic have entered a multi-year collaboration to accelerate the discovery of small molecule drugs using Iambic's AI-driven platform. This partnership aims to improve the efficiency and success rate of identifying new drug candidates in im...
AbbVie presented new data from real-world studies showing VRAYLAR (cariprazine) significantly improves depressive symptoms, functioning, and quality of life in adults with major depressive disorder (MDD) and bipolar I (BP-I) depression. These studies...
AbbVie announced that its investigational drug etentamig met the dual primary endpoints of objective response rate and progression-free survival in a Phase 3 study for relapsed/refractory multiple myeloma. The results were presented at the 23rd Inter...
